{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T20:53:29Z","timestamp":1764276809581},"reference-count":40,"publisher":"The Journal of Rheumatology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To evaluate the effect of brodalumab on psoriasis signs and symptoms assessed by the Psoriasis Symptom Inventory (PSI) in patients with psoriatic arthritis (PsA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>This prespecified analysis of a phase II study (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01516957\">NCT01516957<\/jats:ext-link>) evaluated patients with active PsA and psoriasis-affected body surface area \u2265 3%, randomized to brodalumab (140 or 280 mg) or placebo every 2 weeks (Q2W) for 12 weeks with loading dose at Week 1. At Week 12, patients entering an open-label extension received brodalumab 280 mg Q2W. The PSI measures 8 psoriasis signs and symptoms: itch, redness, scaling, burning, stinging, cracking, flaking, and pain. PSI response is defined as total PSI \u2264 8 (range 0\u201332), each item \u2264 1 (range 0\u20134). PSI scores were assessed at weeks 12 and 24.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>There were 107 eligible patients. At Week 12, mean improvement in PSI scores was 7.8, 11.2, and 1.5 in brodalumab 140 mg, 280 mg, and placebo groups, respectively; by Week 24, improvement was 10.2, 12.4, and 11.7. At Week 12, 75.0%, 81.8%, and 16.7% of patients receiving brodalumab 140 mg, 280 mg, and placebo, respectively, achieved PSI response; improvement was sustained through Week 24, when 83.9% of prior placebo recipients achieved response. At Week 12, 25.0%, 36.4%, and 2.8% of patients receiving brodalumab 140 mg, 280 mg, and placebo, respectively, achieved PSI 0. Percentages improved through Week 24: 40.0% brodalumab 140 mg, 42.9% brodalumab 280 mg, and 48.4% placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Significantly more brodalumab-treated patients with PsA achieved patient-reported improvements in psoriasis signs and symptoms than did those receiving placebo. Improvements were comparable between brodalumab groups.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.150182","type":"journal-article","created":{"date-parts":[[2016,1,16]],"date-time":"2016-01-16T17:18:46Z","timestamp":1452964726000},"page":"343-349","source":"Crossref","is-referenced-by-count":16,"title":["Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic Arthritis"],"prefix":"10.3899","volume":"43","author":[{"given":"Philip J.","family":"Mease","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark C.","family":"Genovese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Mutebi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hema N.","family":"Viswanathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina","family":"Chau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyuan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ngozi","family":"Erondu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Nirula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2016,1,15]]},"reference":[{"key":"2018112909351957000_43.2.343.1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032482"},{"key":"2018112909351957000_43.2.343.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.02.040"},{"key":"2018112909351957000_43.2.343.3","doi-asserted-by":"crossref","first-page":"176298","DOI":"10.1155\/2012\/176298","article-title":"Psoriatic arthritis: an update","volume":"2012","author":"Lloyd","year":"2012","journal-title":"Arthritis"},{"key":"2018112909351957000_43.2.343.4","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jaad.2005.03.046","article-title":"Epidemiology of psoriatic arthritis in the population of the United States","volume":"53","author":"Gelfand","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"2018112909351957000_43.2.343.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.07.023"},{"key":"2018112909351957000_43.2.343.6","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32835fd8d5"},{"key":"2018112909351957000_43.2.343.7","first-page":"680","article-title":"The burden of psoriatic arthritis: a literature review from a global health systems perspective","volume":"35","author":"Lee","year":"2010","journal-title":"P T"},{"key":"2018112909351957000_43.2.343.8","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg384"},{"key":"2018112909351957000_43.2.343.9","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg217"},{"key":"2018112909351957000_43.2.343.10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052935"},{"key":"2018112909351957000_43.2.343.11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020279"},{"key":"2018112909351957000_43.2.343.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.09023.x"},{"key":"2018112909351957000_43.2.343.13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker365"},{"key":"2018112909351957000_43.2.343.14","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.094946"},{"key":"2018112909351957000_43.2.343.15","doi-asserted-by":"publisher","DOI":"10.1186\/ar4317"},{"key":"2018112909351957000_43.2.343.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2008.04.017"},{"key":"2018112909351957000_43.2.343.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.27622"},{"key":"2018112909351957000_43.2.343.18","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5701213"},{"key":"2018112909351957000_43.2.343.19","doi-asserted-by":"crossref","first-page":"539683","DOI":"10.1155\/2012\/539683","article-title":"The Th17\/IL-23 axis and natural immunity in psoriatic arthritis","volume":"2012","author":"Maeda","year":"2012","journal-title":"Int J Rheumatol"},{"key":"2018112909351957000_43.2.343.20","doi-asserted-by":"publisher","DOI":"10.1002\/art.24568"},{"key":"2018112909351957000_43.2.343.21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00628.x"},{"key":"2018112909351957000_43.2.343.22","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20041257"},{"key":"2018112909351957000_43.2.343.23","doi-asserted-by":"publisher","DOI":"10.1038\/ni1261"},{"key":"2018112909351957000_43.2.343.24","doi-asserted-by":"publisher","DOI":"10.1172\/JCI5703"},{"key":"2018112909351957000_43.2.343.25","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.11.7791"},{"key":"2018112909351957000_43.2.343.26","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20061308"},{"key":"2018112909351957000_43.2.343.27","doi-asserted-by":"publisher","DOI":"10.1002\/art.23655"},{"key":"2018112909351957000_43.2.343.28","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-011-1036-6"},{"key":"2018112909351957000_43.2.343.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109017"},{"key":"2018112909351957000_43.2.343.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315231"},{"key":"2018112909351957000_43.2.343.31","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2012.742950"},{"key":"2018112909351957000_43.2.343.32","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.091093"},{"key":"2018112909351957000_43.2.343.33","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12636"},{"key":"2018112909351957000_43.2.343.34","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2012.759639"},{"key":"2018112909351957000_43.2.343.35","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2013.769042"},{"issue":"Suppl2","key":"2018112909351957000_43.2.343.36","first-page":"1054","article-title":"Reliability and construct validity of the Psoriasis Symptom Inventory in subjects with psoriatic arthritis","volume":"73","author":"Mease","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2018112909351957000_43.2.343.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2011.12.003"},{"key":"2018112909351957000_43.2.343.38","unstructured":"United States Food and Drug Administration . Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. [Internet. Accessed October 6, 2015.] Available from: www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM193282"},{"key":"2018112909351957000_43.2.343.39","first-page":"322","article-title":"Etanercept improves psoriatic arthritis patient-reported outcomes: results from EDUCATE","volume":"79","author":"Frankel","year":"2007","journal-title":"Cutis"},{"key":"2018112909351957000_43.2.343.40","first-page":"2262","article-title":"Outcome measures in psoriatic arthritis","volume":"32","author":"Gladman","year":"2005","journal-title":"J Rheumatol"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.150182","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T19:02:25Z","timestamp":1543518145000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.150182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,15]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,2,1]]},"published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.3899\/jrheum.150182"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.150182","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,15]]}}}